Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

PRO: A Deeper Dive Into The Numinus + Novamind Merger

Apr 15 • 2 min read

Earlier this week, Numinus Wellness Inc. (NUMI) struck a deal to acquire Toronto-based Novamind (NM) for approximately $20.8 million, marking one the of largest mergers to date inside the public psychedelic sector. For the past couple of years, Novamind, which operates solely in the United States, has made significant advances toward establishing a stronghold in…

PRO: Comparing The Largest Psychedelic Companies Post Earnings

Apr 8 • 1 min read

Another year, another set of blockbuster year-end results from the three most talked about companies in psychedelics. Mind Medicine (MNMD), Compass Pathways (CMPS), and atai Life Sciences (ATAI) have all greatly benefited from 2021’s banner year. With a handful of successful funding rounds, strategic partnerships, and their continuous push for drug development, the “Big 3”…

Multiple Psychedelics Companies Come Together In a Watershed Moment For Psilocybin Therapy

Apr 4 • 3 min read

On January 5, 2022, Health Canada amended their Food and Drug Regulations to allow practitioners to request access to previously prohibited drugs such as psilocybin, MDMA, and other psychedelic treatments through a new Special Access Program (SAP). The amendment which reversed a policy from 2013 that prohibited special access to restricted drugs was seen as…

PRO: Rapid Reactions To ATAI’s 2021 Year-End Financial Results

Apr 1 • 1 min read

atai Life Sciences (ATAI), the largest pureplay clinical-stage psychedelic company in our index, just reported financial results for the fourth quarter and full-year ended December 31, 2021. The announcement falls on the heels of Compass Pathways (CMPS), Field Trip Health (FTRP), and Mind Medicine (MNMD) all announcing their year-end results, marking a suitable time for…

PRO: Rapid Reactions To Mind Medicine’s 2021 Year-End Financial Results

Mar 29 • 1 min read

Mind Medicine (MindMed) Inc. (MNMD), one of the sector’s largest clinical stage biopharmaceutical companies focused on developing novel products to treat brain health disorders, reported its financial results for the full-year ended December 31, 2021 earlier this week. Like most companies in the space, it’s been relatively difficult to report meaningful revenue. And MindMed, despite…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354